Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion.

Zeng, Qiqun; Saghafinia, Sadegh; Chryplewicz, Agnieszka; Fournier, Nadine; Christe, Lucine; Xie, Yu-Qing; Guillot, Jeremy; Yucel, Simge; Li, Pumin; Galván, José A; Karamitopoulou, Eva; Zlobec, Inti; Ataca, Dalya; Gallean, Fleuriane; Zhang, Peng; Rodríguez-Calero, José Antonio; Rubin, Mark; Tichet, Mélanie; Homicsko, Krisztian and Hanahan, Douglas (2022). Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion. Science, 378(6621), eabl7207. American Association for the Advancement of Science 10.1126/science.abl7207

[img] Text
science.abl7207.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (3MB) | Request a copy

Many human cancers manifest the capability to circumvent attack by the adaptive immune system. In this work, we identified a component of immune evasion that involves frequent up-regulation of fragile X mental retardation protein (FMRP) in solid tumors. FMRP represses immune attack, as revealed by cancer cells engineered to lack its expression. FMRP-deficient tumors were infiltrated by activated T cells that impaired tumor growth and enhanced survival in mice. Mechanistically, FMRP's immunosuppression was multifactorial, involving repression of the chemoattractant C-C motif chemokine ligand 7 (CCL7) concomitant with up-regulation of three immunomodulators-interleukin-33 (IL-33), tumor-secreted protein S (PROS1), and extracellular vesicles. Gene signatures associate FMRP's cancer network with poor prognosis and response to therapy in cancer patients. Collectively, FMRP is implicated as a regulator that orchestrates a multifaceted barrier to antitumor immune responses.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)
04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology > Translational Research Unit

UniBE Contributor:

Christe, Lucine Constance; Galván Hernández, José Alberto; Karamitopoulou Diamantis, Evanthia; Zlobec, Inti; Rodríguez Calero, José Antonio and Rubin, Mark Andrew

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

1095-9203

Publisher:

American Association for the Advancement of Science

Language:

English

Submitter:

Pubmed Import

Date Deposited:

18 Nov 2022 16:16

Last Modified:

05 Dec 2022 16:28

Publisher DOI:

10.1126/science.abl7207

PubMed ID:

36395212

BORIS DOI:

10.48350/174869

URI:

https://boris.unibe.ch/id/eprint/174869

Actions (login required)

Edit item Edit item
Provide Feedback